Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1472
Shown on this page
12
Current sort
Recently updated
Campus scope
Emory University (Winship Cancer Institute), Atlanta, GA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Emory University (Winship Cancer Institute), Atlanta, GA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 565–576 of 1,472 matching trials with a site at Emory University (Winship Cancer Institute), Atlanta, GA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562
Site status not listed — check the official record
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
17
States / cities
Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Not applicable Interventional

The Fourth Left Atrial Appendage Occlusion Study

NCT05963698
Status at this site: Recruiting
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Interventions
WATCHMAN device
Device
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Phase 3 Interventional

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat A, Etavopivat B, Etavopivat C
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235
Status at this site: Recruiting
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Phase 2Phase 3 Interventional

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796
Status at this site: Recruiting
View directory record Official record
Conditions
Neoplasms
Interventions
Gene-modified (GM) T cell therapy
Genetic
Lead sponsor
Celgene
Industry
Eligibility
Not listed
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
103
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Phase 3 Interventional

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT06790784
Status at this site: Recruiting
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
Procedure · Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
34
States / cities
Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Active, not recruiting Phase 3 Interventional

Bionic Pancreas in CFRD

NCT06449677
Site status not listed — check the official record
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
iLet Bionic Pancreas System (BP), Usual Care (UC)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
14 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

NCT04647253
Site status not listed — check the official record
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
AGENT DCB, PTCA balloon catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

NCT07396584
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
HMPL-A580
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Orange, California • Plantation, Florida • Tamarac, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Phase 2 Interventional

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

NCT07459634
Status at this site: Recruiting
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Lurbinectedin, Durvalumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Recruiting Phase 2 Interventional

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

NCT07103746
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Ublituximab, Placebo for Ublituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 4:50 AM EDT
Not yet recruiting Phase 4 Interventional

The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

NCT07824167
Site status not listed — check the official record
View directory record Official record
Conditions
RSV Infection
Interventions
Clesrovimab
Biological
Lead sponsor
Emory University
Other
Eligibility
Up to 8 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 4:50 AM EDT

About this Emory University (Winship Cancer Institute) institution page

What this page lists
ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.